BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Systemic Lupus Erythematosus readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Systemic Lupus Erythe
 matosus\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07260877-5644@assetmemo.bio
DTSTAMP:20261122T012611Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:VENT-03: Phase 2 readout est. (NCT07260877)
DESCRIPTION:VENT-03\, phase 2\, Systemic Lupus Erythematosus.\nStudy: A Mul
 ticenter\, Randomized\, Double-Blind\, Placebo-Controlled\, Phase 2a Study
  With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-0
 3 in Adult Participants With Active Cutaneous Lupus Erythematosus With or 
 Without Systemic Lupus Erythematosus\nEstimated primary completion: Decemb
 er 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/vent-03#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07260877
URL:https://assetmemo.bio/drug/vent-03#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06530849-3183@assetmemo.bio
DTSTAMP:20261122T012611Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:AZD0120: Phase 1/2 readout est. (NCT06530849)
DESCRIPTION:AZD0120\, phase 1/2\, Systemic Lupus Erythematosus.\nStudy: A S
 tudy of GC012F Injection in Subjects With Refractory Systemic Lupus Erythe
 matosus\nEstimated primary completion: 1 February 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/azd0120#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06530849
URL:https://assetmemo.bio/drug/azd0120#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05138133-5367@assetmemo.bio
DTSTAMP:20261122T012611Z
DTSTART;VALUE=DATE:20270223
DTEND;VALUE=DATE:20270224
SUMMARY:Anifrolumab: Phase 3 readout est. (NCT05138133)
DESCRIPTION:Anifrolumab\, phase 3\, Systemic Lupus Erythematosus.\nStudy: P
 hase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lu
 pus Nephritis\nEstimated primary completion: 23 February 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/anifrolumab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT05138133
URL:https://assetmemo.bio/drug/anifrolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05843643-12@assetmemo.bio
DTSTAMP:20261122T012611Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Rinvoq (upadacitinib): Phase 3 readout est. (NCT05843643)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 3\, Systemic Lupus Erythematosus.
 \nStudy: Program to Assess Adverse Events and Change in Disease Activity o
 f Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic
  Lupus Erythematosus\nEstimated primary completion: March 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/upadacitinib#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT05843643
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07523542-5559@assetmemo.bio
DTSTAMP:20261122T012611Z
DTSTART;VALUE=DATE:20270314
DTEND;VALUE=DATE:20270315
SUMMARY:Beijing Biotech anti-CD19 CAR-T: Phase 1/2 readout est. (NCT0752354
 2)
DESCRIPTION:Beijing Biotech anti-CD19 CAR-T\, phase 1/2\, Systemic Lupus Er
 ythematosus.\nStudy: SELECT-SLE: Biomarker-Guided CAR-T Target Selection f
 or Refractory Lupus\nEstimated primary completion: 14 March 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/beijing-biotech-anti-cd19-car
 -t#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7523542
URL:https://assetmemo.bio/drug/beijing-biotech-anti-cd19-car-t#upcoming-eve
 nts
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07538154-3146@assetmemo.bio
DTSTAMP:20261122T012611Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:SCTC21C: Phase 1/2 readout est. (NCT07538154)
DESCRIPTION:SCTC21C\, phase 1/2\, Systemic Lupus Erythematosus.\nStudy: A C
 linica Study of SCTC21C in Participants With Systemic Lupus Erythematosus\
 nEstimated primary completion: April 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/sctc21c#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07538154
URL:https://assetmemo.bio/drug/sctc21c#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06406205-1793@assetmemo.bio
DTSTAMP:20261122T012611Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Lupkynis (Voclosporin): Phase 3 readout est. (NCT06406205)
DESCRIPTION:Lupkynis (Voclosporin)\, phase 3\, Systemic Lupus Erythematosus
 .\nStudy: A Study of QLG1074 Combined With Background Therapy in Subjects 
 With Active Lupus Nephritis\nEstimated primary completion: June 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/voclosporin#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06406205
URL:https://assetmemo.bio/drug/voclosporin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05440422-5367@assetmemo.bio
DTSTAMP:20261122T012611Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Anifrolumab: Phase 2 readout est. (NCT05440422)
DESCRIPTION:Anifrolumab\, phase 2\, Systemic Lupus Erythematosus.\nStudy: T
 he Role of Anifrolumab in Improving Markers of Vascular Risk in Patients W
 ith Systemic Lupus Erythematosus (SLE) - IFN-CVD\nEstimated primary comple
 tion: 1 August 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 anifrolumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT05440422
URL:https://assetmemo.bio/drug/anifrolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07564596-10939@assetmemo.bio
DTSTAMP:20261122T012611Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:budoprutug: Phase 1/2 readout est. (NCT07564596)
DESCRIPTION:budoprutug\, phase 1/2\, Systemic Lupus Erythematosus.\nStudy: 
 A Phase 1b/2a Study of Budoprutug in Systemic Lupus Erythematosus (SLE)\nE
 stimated primary completion: September 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/budoprutug#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07564596
URL:https://assetmemo.bio/drug/budoprutug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07447986-3173@assetmemo.bio
DTSTAMP:20261122T012611Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Sanritatug: Phase 2 readout est. (NCT07447986)
DESCRIPTION:Sanritatug\, phase 2\, Systemic Lupus Erythematosus.\nStudy: To
  Evaluate the Efficacy and Safety of SG301 SC Injection in Systemic Lupus 
 Erythematosus\nEstimated primary completion: 30 September 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/sanritatug#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07447986
URL:https://assetmemo.bio/drug/sanritatug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07509892-52@assetmemo.bio
DTSTAMP:20261122T012611Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:TQH3906: Phase 2 readout est. (NCT07509892)
DESCRIPTION:TQH3906\, phase 2\, Systemic Lupus Erythematosus.\nStudy: A Cli
 nical Trial on the Efficacy and Safety of TQH3906 in the Treatment of Syst
 emic Lupus Erythematosus\nEstimated primary completion: November 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/tqh3906#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07509892
URL:https://assetmemo.bio/drug/tqh3906#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07015983-11187@assetmemo.bio
DTSTAMP:20261122T012611Z
DTSTART;VALUE=DATE:20280517
DTEND;VALUE=DATE:20280518
SUMMARY:Zolacabtagene autoleucel: Phase 2 readout est. (NCT07015983)
DESCRIPTION:Zolacabtagene autoleucel\, phase 2\, Systemic Lupus Erythematos
 us.\nStudy: A Study of CC-97540 (BMS-986353 or Zola-cel)\, CD19-Targeted N
 EX-T CAR T Cells\, in Participants With Active SLE Despite Immunosuppressa
 nts (Breakfree-SLE)\nEstimated primary completion: 17 May 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/zolacabtagene-autoleucel#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07015983
URL:https://assetmemo.bio/drug/zolacabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06570798-5632@assetmemo.bio
DTSTAMP:20261122T012611Z
DTSTART;VALUE=DATE:20280806
DTEND;VALUE=DATE:20280807
SUMMARY:Inebilizumab: Phase 2 readout est. (NCT06570798)
DESCRIPTION:Inebilizumab\, phase 2\, Systemic Lupus Erythematosus.\nStudy: 
 A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoi
 mmune Diseases\nEstimated primary completion: 6 August 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/inebilizumab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06570798
URL:https://assetmemo.bio/drug/inebilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06570798-5633@assetmemo.bio
DTSTAMP:20261122T012611Z
DTSTART;VALUE=DATE:20280806
DTEND;VALUE=DATE:20280807
SUMMARY:Blinatumomab: Phase 2 readout est. (NCT06570798)
DESCRIPTION:Blinatumomab\, phase 2\, Systemic Lupus Erythematosus.\nStudy: 
 A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoi
 mmune Diseases\nEstimated primary completion: 6 August 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/blinatumomab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06570798
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07751848-5367@assetmemo.bio
DTSTAMP:20261122T012611Z
DTSTART;VALUE=DATE:20280825
DTEND;VALUE=DATE:20280826
SUMMARY:Anifrolumab: Phase 3 readout est. (NCT07751848)
DESCRIPTION:Anifrolumab\, phase 3\, Systemic Lupus Erythematosus.\nStudy: A
  Study of Outcomes in Chinese Patients Treated With Anifrolumab Who Have A
 ctive Mod-severe Systemic Lupus Erythematosus\nEstimated primary completio
 n: 25 August 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/an
 ifrolumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07751848
URL:https://assetmemo.bio/drug/anifrolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07311200-62@assetmemo.bio
DTSTAMP:20261122T012611Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Nomelcitinib (D-2570): Phase 2 readout est. (NCT07311200)
DESCRIPTION:Nomelcitinib (D-2570)\, phase 2\, Systemic Lupus Erythematosus.
 \nStudy: A Study of D-2570 in Patients With Active Systemic Lupus Erythema
 tosus (SLE)\nEstimated primary completion: 31 August 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/nomelcitinib-d-2570#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07311200
URL:https://assetmemo.bio/drug/nomelcitinib-d-2570#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05835310-5367@assetmemo.bio
DTSTAMP:20261122T012611Z
DTSTART;VALUE=DATE:20281005
DTEND;VALUE=DATE:20281006
SUMMARY:Anifrolumab: Phase 3 readout est. (NCT05835310)
DESCRIPTION:Anifrolumab\, phase 3\, Systemic Lupus Erythematosus.\nStudy: A
 n Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic L
 upus Erythematosus in Pediatric Participants\nEstimated primary completion
 : 5 October 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ani
 frolumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT05835310
URL:https://assetmemo.bio/drug/anifrolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07328581-85@assetmemo.bio
DTSTAMP:20261122T012611Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:ICG318: Phase 2 readout est. (NCT07328581)
DESCRIPTION:ICG318\, phase 2\, Systemic Lupus Erythematosus.\nStudy: A Phas
 e IIa Study of ICG318 CAR-T in Refractory Systemic Lupus Erythematosus Wit
 h or Without Lupus Nephritis\nEstimated primary completion: December 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/icg318#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07328581
URL:https://assetmemo.bio/drug/icg318#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07405970-5444@assetmemo.bio
DTSTAMP:20261122T012611Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Obinutuzumab beta (Bejescin): Phase 3 readout est. (NCT07405970)
DESCRIPTION:Obinutuzumab beta (Bejescin)\, phase 3\, Systemic Lupus Erythem
 atosus.\nStudy: A Phase 3 Clinical Study of MIL62 in Systemic Lupus Erythe
 matosus\nEstimated primary completion: December 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/obinutuzumab-beta-bejescin#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07405970
URL:https://assetmemo.bio/drug/obinutuzumab-beta-bejescin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05799378-5478@assetmemo.bio
DTSTAMP:20261122T012611Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Hydroxychloroquine: Phase 3 readout est. (NCT05799378)
DESCRIPTION:Hydroxychloroquine\, phase 3\, Systemic Lupus Erythematosus.\nS
 tudy: Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease\nEst
 imated primary completion: 31 December 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/hydroxychloroquine#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT05799378
URL:https://assetmemo.bio/drug/hydroxychloroquine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07430306-5367@assetmemo.bio
DTSTAMP:20261122T012611Z
DTSTART;VALUE=DATE:20290126
DTEND;VALUE=DATE:20290127
SUMMARY:Anifrolumab: Phase 3 readout est. (NCT07430306)
DESCRIPTION:Anifrolumab\, phase 3\, Systemic Lupus Erythematosus.\nStudy: A
  Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in I
 mmunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus\n
 Estimated primary completion: 26 January 2029. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/anifrolumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07430306
URL:https://assetmemo.bio/drug/anifrolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07409181-5598@assetmemo.bio
DTSTAMP:20261122T012611Z
DTSTART;VALUE=DATE:20290204
DTEND;VALUE=DATE:20290205
SUMMARY:BI 3000202: Phase 2 readout est. (NCT07409181)
DESCRIPTION:BI 3000202\, phase 2\, Systemic Lupus Erythematosus.\nStudy: A 
 Study to Test Whether Different Doses of BI 3000202 Help People With Syste
 mic Lupus Erythematosus (SLE)\nEstimated primary completion: 4 February 20
 29. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/bi-3000202#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07409181
URL:https://assetmemo.bio/drug/bi-3000202#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06897930-3183@assetmemo.bio
DTSTAMP:20261122T012611Z
DTSTART;VALUE=DATE:20290501
DTEND;VALUE=DATE:20290502
SUMMARY:AZD0120: Phase 1/2 readout est. (NCT06897930)
DESCRIPTION:AZD0120\, phase 1/2\, Systemic Lupus Erythematosus.\nStudy: A S
 tudy to Investigate the Safety\, Tolerability\, and Efficacy of AZD0120 in
  Adults With Refractory SLE\nEstimated primary completion: 1 May 2029. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/azd0120#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06897930
URL:https://assetmemo.bio/drug/azd0120#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07570862-5437@assetmemo.bio
DTSTAMP:20261122T012611Z
DTSTART;VALUE=DATE:20290701
DTEND;VALUE=DATE:20290702
SUMMARY:FT819: Phase 2 readout est. (NCT07570862)
DESCRIPTION:FT819\, phase 2\, Systemic Lupus Erythematosus.\nStudy: A Phase
  2\, Open-Label\, Single-Arm Trial of FT819 in Participants With Lupus Nep
 hritis\nEstimated primary completion: 1 July 2029. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/ft819#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07570862
URL:https://assetmemo.bio/drug/ft819#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07630714-5367@assetmemo.bio
DTSTAMP:20261122T012611Z
DTSTART;VALUE=DATE:20300902
DTEND;VALUE=DATE:20300903
SUMMARY:Anifrolumab: Phase 2 readout est. (NCT07630714)
DESCRIPTION:Anifrolumab\, phase 2\, Systemic Lupus Erythematosus.\nStudy: A
  Study to Investigate Pharmacokinetics\, Pharmacodynamics\, and Safety of 
 Subcutaneous Anifrolumab in Pediatric Participants 5 to < 18 Years of Age 
 With Systemic Lupus Erythematosus\nEstimated primary completion: 2 Septemb
 er 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/anifrolumab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0763
 0714
URL:https://assetmemo.bio/drug/anifrolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07791199-100@assetmemo.bio
DTSTAMP:20261122T012611Z
DTSTART;VALUE=DATE:20301031
DTEND;VALUE=DATE:20301101
SUMMARY:Sotyktu (deucravacitinib): Phase 3 readout est. (NCT07791199)
DESCRIPTION:Sotyktu (deucravacitinib)\, phase 3\, Psoriatic Arthritis.\nStu
 dy: Continued Access to Deucravacitinib for Adult SLE/SjD and Pediatric Ps
 O/PsA Study Completers\nEstimated primary completion: 31 October 2030. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/deucravacitinib#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07791199
URL:https://assetmemo.bio/drug/deucravacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05352919-5645@assetmemo.bio
DTSTAMP:20261122T012611Z
DTSTART;VALUE=DATE:20320503
DTEND;VALUE=DATE:20320504
SUMMARY:Litifilimab: Phase 3 readout est. (NCT05352919)
DESCRIPTION:Litifilimab\, phase 3\, Systemic Lupus Erythematosus.\nStudy: A
  Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) I
 njections and it's Effects on Symptoms in Adults With Systemic Lupus Eryth
 ematosus (SLE)\nEstimated primary completion: 3 May 2032. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/litifilimab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT05352919
URL:https://assetmemo.bio/drug/litifilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07691970-5367@assetmemo.bio
DTSTAMP:20261122T012611Z
DTSTART;VALUE=DATE:20321230
DTEND;VALUE=DATE:20321231
SUMMARY:Anifrolumab: Phase 3 readout est. (NCT07691970)
DESCRIPTION:Anifrolumab\, phase 3\, Systemic Lupus Erythematosus.\nStudy: R
 ollover Study for Participants Who Have Completed a Previous Clinical Stud
 y With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Trea
 tment\nEstimated primary completion: 30 December 2032. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/anifrolumab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07691970
URL:https://assetmemo.bio/drug/anifrolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
